BIOTECHNOLOGY VALUE FUND L P 13D and 13G filings for Syndax Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2023-02-14 11:53 am Sale | 2022-12-31 | 13G | Syndax Pharmaceuticals, Inc. SNDX | BIOTECHNOLOGY VALUE FUND L P | 1,451,197 2.100% | -3,480,682 (-70.58%) | Filing |
| 2022-02-14 1:12 pm Purchase | 2021-12-31 | 13G | Syndax Pharmaceuticals, Inc. SNDX | BIOTECHNOLOGY VALUE FUND L P | 4,931,879 8.900% | 1,221,190 (+32.91%) | Filing |
| 2021-02-12 5:16 pm Purchase | 2020-12-31 | 13G | Syndax Pharmaceuticals, Inc. SNDX | BIOTECHNOLOGY VALUE FUND L P | 3,710,689 7.400% | 894,299 (+31.75%) | Filing |
| 2020-02-14 5:18 pm Purchase | 2019-12-31 | 13G | Syndax Pharmaceuticals, Inc. SNDX | BIOTECHNOLOGY VALUE FUND L P | 2,816,390 9.990% | 280,512 (+11.06%) | Filing |